Article Text

Download PDFPDF
The putative role of isoprostanes in human cardiovascular physiology and disease: following the fingerprints
  1. J-L Cracowski
  1. Correspondence to:
    Dr Jean-Luc Cracowski, Laboratoire de Pharmacologie, Laboratoire HP2, Faculté de Médecine de Grenoble, Domaine de la Merci, 38700 La Tronche, France;
    jean-luc.cracowski{at}ujf-grenoble.fr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Are isoprostanes more than physiopathological biomarkers of lipid peroxidation? Could they play a role in human cardiovascular physiology and disease?

Isoprostanes are arachidonic acid metabolites produced through a free radical dependent mechanism.1 They are formed in situ on phospholipids, at sites of free radical generation. Once released from cell membranes by phospholipases, isoprostanes circulate in the plasma in free form, and are potentially available for agonist receptor interaction.

Increased formation of isoprostanes was first described in cigarette smokers.2 Since this study, their increased formation has been observed in a large number of diseases including atherosclerosis and coronary heart disease.3 Some reports also showed that isoprostanes concentrations were increased in the pericardial fluid and urine of patients suffering from heart failure.4–6 Isoprostane concentrations increased with the functional severity of heart failure. The study by Nonaka-Sarukawa and colleagues in this issue of Heart further supports the hypothesis that oxidative stress, assessed by urinary 15-F2t-isoprostane concentrations, is increased in patients with congestive heart failure and correlates with the severity of the disease.7 They showed that 15-F2t-isoprostane values …

View Full Text